KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Amortization of Deferred Charges: 2020-2025

Historic Amortization of Deferred Charges for Esperion Therapeutics (ESPR) over the last 5 years, with Sep 2025 value amounting to $4.6 million.

  • Esperion Therapeutics' Amortization of Deferred Charges rose 924.61% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year increase of 421.23%. This contributed to the annual value of $1.5 million for FY2024, which is 11.73% down from last year.
  • As of Q3 2025, Esperion Therapeutics' Amortization of Deferred Charges stood at $4.6 million, which was up 23.55% from $3.7 million recorded in Q2 2025.
  • Esperion Therapeutics' Amortization of Deferred Charges' 5-year high stood at $4.6 million during Q3 2025, with a 5-year trough of $172,000 in Q4 2024.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $437,000 (2024), whereas its average is $1.1 million.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first plummeted by 76.62% in 2021, then spiked by 924.61% in 2025.
  • Over the past 5 years, Esperion Therapeutics' Amortization of Deferred Charges (Quarterly) stood at $407,000 in 2021, then increased by 1.72% to $414,000 in 2022, then increased by 4.11% to $431,000 in 2023, then crashed by 60.09% to $172,000 in 2024, then skyrocketed by 924.61% to $4.6 million in 2025.
  • Its last three reported values are $4.6 million in Q3 2025, $3.7 million for Q2 2025, and $699,000 during Q1 2025.